NHS NEL
Demonstration Formulary
3 Respiratory system
03-07 Dornase alfa
Dornase Alfa
Pulmozyme
®
Formulary
Commissioned by NHSE for Cystic Fibrosis only
Links
BCICB Asthma Treatment Guidelines - Adolescents 12-17 years old
BCICB Asthma Treatment Guidelines - Adults 18+
BCICB Asthma Treatment Guidelines For Children Under 12
BCICB COPD Inhaler Treatment Guidelines
BCICB Difficult Asthma Referral Pathway - Adults 18+
Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations)
COVID-19: information for the respiratory community
Greener Inhaler Guide Switching Information
How to improve respiratory control in asthma and COPD
NICE CG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
NICE TA138: Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation (TA266)
NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
NICE TA398: Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
TA266: Mannitol dry powder for inhalation for treating cystic fibrosis
Key
Full Site